The results were consistent with the TCGA cohort, in terms of the relatively higher frequency of TP53 mutations, fewer co-mutations, and lower TMB compared to RET fusion-negative NSCLC patients. The gene discussed is TP53; the disease is non-small cell lung carcinoma.